Catch Them. You Can.


PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information [External link]

Patients with diabetes* have been specifically identified as an ‘at-risk’ group for increased susceptibility to pneumococcal infection.1,2

Recognise the risk (reference 2), prevent your diabetes patients from falling through the cracks*, help protect them against pneumococcal disease with pPV23 - references 1,3
Young man testing blood sugar levels using a finger tip testing device

PPV coverage in diabetes* patients up to March 20224

Approximately 43.8%

of diabetes patients were unprotected against pneumococcal disease in 20224

Order and start vaccinating today

Check PPV23 stock status

You can help protect your patients from pneumococcal disease all year round by offering PNEUMOVAX® 23 (PPV23) as part of the NHS National Immunisation Programme.1,3

Pneumococcal disease is an infection caused by the Streptococcus pneumoniae bacterium (pneumococcus)1,5

Invasive pneumococcal infections caused by S. pneumoniae occur inside a major organ (such as the lungs) or the blood, and tend to cause more serious disease, like pneumonia5 – a leading cause of death in the UK.6

Want to learn more? Visit our About pneumococcal disease page.

Adults with diabetes are ~3x more likely to get a pneumococcal infection than healthy adults7

Diabetes patients may have abnormalities in immune function that affect their reaction to infection, including deficiencies in: antibody response, cell-mediated immunity, leukocyte function and colonisation rates.8

Unlike seasonal influenza, the chronic nature of diabetes means affected individuals are at risk of pneumococcal disease all year round, not only in the winter.2

Middle-aged man coughing into his hand

Along with an increased risk of infection, patients with diabetes have an increased susceptibility to complications from pneumococcal disease, and poorer outcomes8

Pneumonia is responsible for nearly 1 in 3 cases of hospitalisation with longer hospital stays in diabetes patients.9–11

In a meta-analysis of 33,000 patients with CAP, the mortality rate among patients with diabetes mellitus was 1.3x higher.12

Increased susceptibility to infection may be due to hyperglycaemia, which increases the risk of:13

  • Reduced lung aspiration function
  • Increased pulmonary microangiopathy
  • Reduced immunity
  • Impaired lung structure
  • Increased oxidative stress 

Offer/administer PNEUMOVAX® 23 at your surgery all year round, to prevent your patients from falling through the cracks1,3

Public health policy recommends PPV23 in patients with diabetes mellitus,* as part of the NHS National Immunisation Programme in the UK† - references 1,3

PNEUMOVAX® 23 offers immunisation against pneumococcal infections in ‘at-risk’ patients 2 years old and older with diabetes.*1

You only need a single 0.5 mL dose (injected subcutaneously or intramuscularly) for most of your eligible patients.‡1,3

Efficacy data

For more information on the safety of PNEUMOVAX® 23, visit our Safety information page.

PPV23 is in stock§ and available to order via ImmForm as part of the National Immunisation Programme, and can be given to your COPD patients at any time during the year1,16,17 

Check PPV23 stock status

Find further resources on the use of PPV23 in your eligible patients on our Resources page

*Diabetes requiring insulin or antidiabetic medication.
PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine) is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults.3
Revaccination may be needed in certain at-risk groups. The timing and need of revaccination should be determined on the basis of official recommendations and in line with the SmPC.1,3
Subject to supply.

CAP = community acquired pneumonia; PPV = pneumococcal polysaccharide vaccine; SmPC = Summary of Product Characteristics.


  1. The Green Book – Immunisation against infectious disease (January 2020). Chapter 25 – Pneumococcal. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/ 857267/GB_Chapter_25_pneumococcal_January_2020.pdf.
  2. Torres A, et al. Thorax 2015;70(10):984–989.
  3. Pneumovax-23 Summary of Product Characteristics.
  4. UK Health Security Agency. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2021 to March 2022. Available at: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates/pneumococcal-polysaccharide-vaccine-ppv-coverage-report-england-april-2021-to-march-2022.
  5. NHS Inform. Pneumococcal infections. Available at: https://www.nhsinform.scot/illnesses-and-conditions/infections-and-poisoning/pneumococcal-infections.
  6. Office for National Statistics. Leading causes of death, UK: 2001 to 2018. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/articles/leadingcaus esofdeathuk/2001to2018.
  7. Al-Dahash R, et al. Cureus. 2022;14(3):e23612.
  8. Flynn T, Lesser C. Understanding the Importance of Pneumococcal Disease Prevention in Patients With Diabetes. Available at: https://www.pharmacytimes.com/view/understanding-the-importance-of-pneumococcal-disease -prevention-in-patients-with-diabetes.
  9. Falcone M, et al. Medicine (Baltimore). 2016;95(5):e2531.
  10. Ghit, A. Egypt J Intern Med. 2023;35:16.
  11. Martins M, et al. BMJ Open Diabetes Res Care. 2016;4:e000181.
  12. Sözen M, et al. J Diabetes Metab Disord. 2021; 20(1):757–763.
  13. Abbasi E, et al. Metabol Open. 2021; 11: 100122.
  14. Kuo CS, et al. Medicine (Baltimore). 2016; 95(26): e4064.
  15. Lawrence H, et al. PLoS Med. 2020;17(10):e1003326.
  16. UK Health Security Agency. The complete routine immunisation schedule from February 2022.
  17. National Institute for Health and Care Excellence. BNF Pneumococcal vaccine. Available at: https://bnf.nice.org.uk/treatment-summaries/pneumococcal-vaccine/.

By clicking the links above you will leave the MSD Connect website and be taken to third-party websites

Supporting documentation

PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information

By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website